Table 3 Annual percent change in age and sex-standardized incidence rates of primary CNS tumors (reference: French National Census 2000–2012) according to sex, age, histology, malignancy status and urban/rural place of residence, Gironde CNS registry, 2000–2012
n | period | APC | 95% CI, APC | Trend P-value | |
|---|---|---|---|---|---|
All CNS Tumorsa | 3515 | 2000–2012 | + 2.7 | (+ 1.8; + 3.7) | < 0.0001 |
Sex | |||||
Male | 1526 | 2000–2012 | + 1.8 | (+ 0.3; + 3.3) | 0.006 |
Female | 1989 | 2000–2012 | + 3.6 | (+ 2.2; + 5.0) | < 0.0001 |
Age | |||||
0–24 y | 254 | 2000–2012 | + 0.6 | (−2.5; + 3.8) | 0.7 |
25–49 y | 730 | 2000–2012 | + 1.2 | (− 0.9; + 3.4) | 0.2 |
50–64 y | 1088 | 2000–2012 | + 1.2 | (− 0.6; + 3.1) | 0.2 |
65–79 y | 1000 | 2000–2012 | + 3.0 | (+ 0.8; + 5.2) | 0.002 |
80 y and overb | 443 | 2000–2002 | + 62 | (+ 27; + 108) | < 0.0001 |
2002–2012 | + 1.4 | (− 2.4; + 5.4) | 0.4 | ||
Place of residence | |||||
Urban | 2835 | 2000–2012 | + 2.4 | (+ 1.6; + 3.2) | < 0.0001 |
Rural | 680 | 2000–2012 | + 4.0 | (+ 1.4; + 6.8) | 0.0008 |
Histological confirmation | |||||
Yes | 2706 | 2000–2012 | + 2.1 | (+ 1.1; + 3.2) | < 0.0001 |
No | 809 | 2000–2012 | + 4.8 | (+ 2.8; + 6.9) | < 0.0001 |
Malignant tumors(/3) | 1548 | 2000–2012 | + 1.3 | (− 0.20; + 2.8) | 0.06 |
Sex | |||||
Male | 860 | 2000–2012 | + 0.99 | (− 0.82; + 2.8) | 0.2 |
Female | 688 | 2000–2012 | + 1.7 | (−0.42; + 3.9) | 0.1 |
Age | |||||
0–24 y | 122 | 2000–2012 | + 0.90 | (− 3.5; + 5.5) | 0.6 |
25–49 y | 268 | 2000–2012 | − 1.2 | (− 5.9; + 3.7) | 0.6 |
50–64 y | 457 | 2000–2012 | + 1.4 | (− 1.3; + 4.2) | 0.2 |
65–79 y | 513 | 2000–2012 | + 1.3 | (−1.4; + 4.0) | 0.3 |
80 y and over | 188 | 2000–2012 | + 2.0 | (−4.0; + 8.4) | 0.5 |
Non-malignant tumors (/1, /0) | 1967 | 2000–2012 | + 4.0 | (+ 2.7 − + 5.3) | < 0.0001 |
Sex | |||||
Male | 666 | 2000–2012 | + 3.1 | (+ 0.35; + 5.8) | 0.01 |
Female | 1301 | 2000–2012 | + 4.6 | (+ 2.6; + 6.7) | < 0.0001 |
Age | |||||
0–24 y | 132 | 2000–2012 | + 0.53 | (−3.3; + 4.5) | 0.8 |
25–49 y | 462 | 2000–2012 | + 2.8 | (+ 0.35; + 5.3) | 0.01 |
50–64 y | 631 | 2000–2012 | + 1.3 | (−1.3; + 3.9) | 0.3 |
65–79 y | 487 | 2000–2012 | + 4.8 | (+ 2.3; + 7.4) | < 0.0001 |
80 y and overb | 255 | 2000–2002 | + 103 | (+ 5.1; + 292) | 0.01 |
2002–2012 | + 4.5 | (−0.70; + 10) | 0.05 | ||
Neuroepithelial tumors | 1496 | 2000–2012 | + 1.5 | (−0.34; + 3.5) | 0.1 |
Sex | |||||
Male | 843 | 2000–2012 | + 1.5 | (−0.64; + 3.6) | 0.1 |
Female | 653 | 2000–2012 | + 1.6 | (−0.54; + 3.9) | 0.1 |
Age | |||||
0–24 y | 179 | 2000–2012 | + 1.3 | (−3.8; + 6.6) | 0.6 |
25–49 y | 278 | 2000–2012 | −1.1 | (−5.9; + 4.0) | 0.6 |
50–64 y | 430 | 2000–2012 | + 1.6 | (−0.95; + 4.2) | 0.2 |
65–79 y | 458 | 2000–2012 | + 1.5 | (−1.5; + 4.6) | 0.3 |
80 y and over | 151 | 2000–2012 | + 3.7 | (−1.9; + 9.7) | 0.1 |
Meningeal tumors | 1321 | 2000–2012 | + 5.4 | (+ 3.8; + 7.0) | < 0.0001 |
Sex | |||||
Male | 346 | 2000–2012 | + 6.1 | (+ 0.82; + 11) | 0.01 |
Female | 975 | 2000–2012 | + 5.6 | (+ 3.4; + 7.8) | < 0.0001 |
Age | |||||
0–24 y | 24 | 2000–2012 | |||
25–49 y | 258 | 2000–2012 | + 4.2 | (+ 0.75; + 7.8) | 0.007 |
50–64 y | 445 | 2000–2012 | + 1.5 | (−1.1; + 4.2) | 0.2 |
65–79 y | 375 | 2000–2012 | + 5.8 | (+ 2.5; + 9.2) | < 0.0001 |
80 y and over | 219 | 2000–2012 | + 11 | (+ 5.1; + 17) | < 0.0001 |
Other histological subtypes | |||||
Cranial and spinal nerve tumors | 422 | 2000–2012 | + 0.68 | (−0.75; + 2.1) | 0.3 |
Lymphomas | 115 | 2000–2012 | + 3.6 | (−3.5; + 11) | 0.3 |
Other tumorsc | 161 | 2000–2012 | − 1.2 | (−6.6; + 4.5) | 0.6 |